Stonegate Capital Partners Updates Coverage on Cingulate Inc., Highlights CTx-1301 ADHD Treatment Progress

Stonegate Capital Partners has updated its coverage of Cingulate Inc., highlighting continued progress toward the potential commercial launch of the company’s ADHD treatment candidate CTx-1301. According to the analysis, the regulatory focus has shifted to manufacturing processes rather than clinical performance, with the New Drug Application remaining under FDA review through the 505(b)(2) pathway.

The firm noted that FDA feedback has been limited to Chemistry, Manufacturing, and Controls matters, with no safety or efficacy concerns identified. This positions the remaining work as addressable process validation rather than clinical risk. While regulatory timing may shift due to manufacturing validation requirements, approval remains likely according to the analysis.

Cingulate’s financial position appears supportive of ongoing regulatory and manufacturing activities. Following a $12 million private investment in public equity completed in February 2026, the company maintains a pro forma cash balance of approximately $23 million, which Stonegate estimates provides runway into late 2026. The company also maintains access to capital through its at-the-market and equity line of credit facilities.

The market opportunity for CTx-1301 remains substantial, with the ADHD treatment market representing significant commercial potential. According to company disclosures cited in the analysis, capturing just 1% market share could translate to approximately $250 million in revenue potential for CTx-1301. The treatment primarily targets the booster-dose segment within the broader ADHD market.

Stonegate’s analysis suggests that recent financing, intellectual property progress, and commercial buildout efforts continue to support the broader investment thesis for Cingulate. The full announcement with additional details is available at https://www.stonegateinc.com. The regulatory pathway forward appears focused on resolving remaining manufacturing items as the company works toward potential commercial launch of its ADHD treatment candidate.

This news story relied on content distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Stonegate Capital Partners Updates Coverage on Cingulate Inc., Highlights CTx-1301 ADHD Treatment Progress.

The post Stonegate Capital Partners Updates Coverage on Cingulate Inc., Highlights CTx-1301 ADHD Treatment Progress appeared first on citybuzz.